384 related articles for article (PubMed ID: 27401940)
1. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
[TBL] [Abstract][Full Text] [Related]
2. [Infrastructure for the clinical research of muscular dystrophies: remudy and MDCTN].
Kimura E; Nakamura H; Mitsuhashi S; Takeuchi F; Mori-Yoshimura M; Shimizu R; Komaki H; Hayashi YK; Nishino I; Kawai M; Takeda S
Rinsho Shinkeigaku; 2014; 54(12):1069-70. PubMed ID: 25519964
[TBL] [Abstract][Full Text] [Related]
3. [Registry of muscular dystrophy (Remudy). Construction of the patient self-report registry and collaboration with overseas network].
Nakamura H; Kawai M
Rinsho Shinkeigaku; 2011 Nov; 51(11):901-2. PubMed ID: 22277410
[TBL] [Abstract][Full Text] [Related]
4. [Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy)].
Nakamura H; Kimura E; Kawai M
Brain Nerve; 2011 Nov; 63(11):1279-84. PubMed ID: 22068481
[TBL] [Abstract][Full Text] [Related]
5. [Remudy].
Kimura E; Nakamura H; Nishino I
Brain Nerve; 2014 Nov; 66(11):1396-402. PubMed ID: 25407075
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of an evaluation method for muscular dystrophy and a patient registration system for clinical trials].
Kawai M
Rinsho Shinkeigaku; 2009 Nov; 49(11):863-6. PubMed ID: 20030232
[TBL] [Abstract][Full Text] [Related]
7. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
Trials; 2018 May; 19(1):291. PubMed ID: 29793540
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy).
Nakamura H; Kimura E; Mori-Yoshimura M; Komaki H; Matsuda Y; Goto K; Hayashi YK; Nishino I; Takeda S; Kawai M
Orphanet J Rare Dis; 2013 Apr; 8():60. PubMed ID: 23601510
[TBL] [Abstract][Full Text] [Related]
9. The Muscular Dystrophy Association's neuroMuscular ObserVational Research Data Hub (MOVR): Design, Methods, and Initial Observations.
Kilroy EA; Burris R; Javelosa E; Waits J; Lek A; Rodgers R; Opgenorth H; Hesterlee S
J Neuromuscul Dis; 2023; 10(3):365-380. PubMed ID: 36911943
[TBL] [Abstract][Full Text] [Related]
10. Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials.
Furlong P; Dugar A; White M
Res Involv Engagem; 2024 Jan; 10(1):1. PubMed ID: 38167117
[TBL] [Abstract][Full Text] [Related]
11. Background, introduction and activity of the Japan Primary Registries Network.
Shiokawa T
J Evid Based Med; 2009 Feb; 2(1):41-3. PubMed ID: 21348982
[TBL] [Abstract][Full Text] [Related]
12. Accelerating Rare Disease Drug Development: Lessons Learned from Muscular Dystrophy Patient Advocacy Groups.
Huml RA; Dawson J; Bailey M; Nakas N; Williams J; Kolochavina M; Huml JR
Ther Innov Regul Sci; 2021 Mar; 55(2):370-377. PubMed ID: 32974874
[TBL] [Abstract][Full Text] [Related]
13. Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders.
Peay HL; Biesecker BB; Wilfond BS; Jarecki J; Umstead KL; Escolar DM; Tibben A
Clin Trials; 2018 Apr; 15(2):139-148. PubMed ID: 29475375
[TBL] [Abstract][Full Text] [Related]
14. Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011.
Do TN; Street N; Donnelly J; Adams MM; Cunniff C; Fox DJ; Weinert RO; Oleszek J; Romitti PA; Westfield CP; Bolen J;
Birth Defects Res; 2018 Nov; 110(19):1404-1411. PubMed ID: 30070776
[TBL] [Abstract][Full Text] [Related]
15. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia.
Bladen CL; Rafferty K; Straub V; Monges S; Moresco A; Dawkins H; Roy A; Chamova T; Guergueltcheva V; Korngut L; Campbell C; Dai Y; Barišić N; Kos T; Brabec P; Rahbek J; Lahdetie J; Tuffery-Giraud S; Claustres M; Leturcq F; Ben Yaou R; Walter MC; Schreiber O; Karcagi V; Herczegfalvi A; Viswanathan V; Bayat F; de la Caridad Guerrero Sarmiento I; Ambrosini A; Ceradini F; Kimura E; van den Bergen JC; Rodrigues M; Roxburgh R; Lusakowska A; Oliveira J; Santos R; Neagu E; Butoianu N; Artemieva S; Rasic VM; Posada M; Palau F; Lindvall B; Bloetzer C; Karaduman A; Topaloğlu H; Inal S; Oflazer P; Stringer A; Shatillo AV; Martin AS; Peay H; Flanigan KM; Salgado D; von Rekowski B; Lynn S; Heslop E; Gainotti S; Taruscio D; Kirschner J; Verschuuren J; Bushby K; Béroud C; Lochmüller H
Hum Mutat; 2013 Nov; 34(11):1449-57. PubMed ID: 23913485
[TBL] [Abstract][Full Text] [Related]
16. Duchenne muscular dystrophy: clinical trials and emerging tribulations.
Shieh PB
Curr Opin Neurol; 2015 Oct; 28(5):542-6. PubMed ID: 26280938
[TBL] [Abstract][Full Text] [Related]
17. [Molecular therapies: present and future in neuromuscular diseases].
Ziegler A; Walter MC; Schoser BE
Nervenarzt; 2023 Jun; 94(6):473-487. PubMed ID: 37221259
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of progressive muscular dystrophy in Okinawa, Japan. Classification with molecular biological techniques.
Nakagawa M; Nakahara K; Yoshidome H; Suehara M; Higuchi I; Fujiyama J; Nakamura A; Kubota R; Takenaga S; Arahata K
Neuroepidemiology; 1991; 10(4):185-91. PubMed ID: 1745328
[TBL] [Abstract][Full Text] [Related]
19. Engaging Participants in Rare Disease Research: A Qualitative Study of Duchenne Muscular Dystrophy.
Bendixen RM; Morgenroth LP; Clinard KL
Clin Ther; 2016 Jun; 38(6):1474-1484.e2. PubMed ID: 27136712
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China.
Li X; Zhao L; Zhou S; Hu C; Shi Y; Shi W; Li H; Liu F; Wu B; Wang Y
Orphanet J Rare Dis; 2015 Jan; 10():5. PubMed ID: 25612904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
